Sagar, Divya <br/><br/>
Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.  [electronic resource] 

 -  Scientific reports  06 2017 
 - 2707 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-017-03027-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Blocking--pharmacology<br/>Central Nervous System--immunology<br/>Chemokine CCL2--metabolism<br/>Dendritic Cells--drug effects<br/>Encephalomyelitis, Autoimmune, Experimental--diagnosis<br/>Endothelium, Vascular--metabolism<br/>Immunity--drug effects<br/>Lectins--genetics<br/>Lectins, C-Type--antagonists & inhibitors<br/>Mice<br/>Mice, Knockout<br/>Models, Biological<br/>Myeloid Cells--drug effects<br/>Phenotype<br/>Protein Binding<br/>Protein Tyrosine Phosphatase, Non-Receptor Type 11--metabolism<br/>Protein Tyrosine Phosphatase, Non-Receptor Type 6--metabolism<br/>Receptors, Mitogen--antagonists & inhibitors<br/>Recurrence<br/>Severity of Illness Index<br/>Signal Transduction<br/>Transendothelial and Transepithelial Migration